Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F.
Mohamed AM, et al. Among authors: wattel e.
Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898.
Oncotarget. 2016.
PMID: 26284582
Free PMC article.